Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
Adelene Y. L. Sim, Sumit Barua, Jong Youl Kim, et al.
Frontiers in Neuroscience (2021) Vol. 15
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Neuroprotective Effect of SGLT2 Inhibitors
Agnieszka Pawlos, Marlena Broncel, Ewelina Woźniak, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7213-7213
Open Access | Times Cited: 173
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 40
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system
Jiaqi Mei, Yi Li, Liyan Niu, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 15
Comparative Effectiveness of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Preventing Alzheimer's Disease, Vascular Dementia, and Other Dementia Types Among Patients with Type 2 Diabetes
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes & Metabolism (2025), pp. 101623-101623
Closed Access | Times Cited: 1
Aberrant energy metabolism in Alzheimer’s disease
Linjie Yu, Jiali Jin, Yun Xu, et al.
Journal of Translational Internal Medicine (2022) Vol. 10, Iss. 3, pp. 197-206
Open Access | Times Cited: 30
Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats
Xiying Guo, Min Lei, Jiangyan Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways
Francesca Mancinetti, Dionysios P. Xenos, Michelantonio De Fano, et al.
Ageing Research Reviews (2023) Vol. 90, pp. 102018-102018
Closed Access | Times Cited: 20
Dapagliflozin Ameliorates Cognitive Impairment in Aluminum-Chloride-Induced Alzheimer’s Disease via Modulation of AMPK/mTOR, Oxidative Stress and Glucose Metabolism
Waad A. Samman, Salma Selim, Hassan M. El Fayoumi, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 5, pp. 753-753
Open Access | Times Cited: 18
SGLT2 and DPP4 inhibitors improve Alzheimer’s disease–like pathology and cognitive function through distinct mechanisms in a T2D–AD mouse model
Adelene Y. L. Sim, Da Hyun Choi, Jong Youl Kim, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 168, pp. 115755-115755
Open Access | Times Cited: 17
GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
Magdalena Złotek, Antonina Kurowska, Mariola Herbet, et al.
Biomedicines (2023) Vol. 11, Iss. 11, pp. 3035-3035
Open Access | Times Cited: 17
Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer’s disease: a narrative review
Xin Jiang, Ji Li, Xiaohui Yao, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 6
Risk of Dementia and Alzheimer's Disease Associated With Antidiabetics: A Bayesian Network Meta-Analysis
Yongjun Sunwoo, Jaeho Park, Chang-Young Choi, et al.
American Journal of Preventive Medicine (2024) Vol. 67, Iss. 3, pp. 434-443
Closed Access | Times Cited: 6
Intranasal Administration of KYCCSRK Peptide Rescues Brain Insulin Signaling Activation and Reduces Alzheimer’s Disease-like Neuropathology in a Mouse Model for Down Syndrome
Antonella Tramutola, Simona Lanzillotta, Giuseppe Aceto, et al.
Antioxidants (2023) Vol. 12, Iss. 1, pp. 111-111
Open Access | Times Cited: 15
Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice
Iwona Piątkowska‐Chmiel, Mariola Herbet, Monika Gawrońska‐Grzywacz, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 983-1000
Open Access | Times Cited: 14
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides
Kuldeep Singh, Jeetendra Kumar Gupta, Shivendra Kumar, et al.
Current Protein and Peptide Science (2024) Vol. 25, Iss. 7, pp. 507-526
Closed Access | Times Cited: 5
The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer's disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation
Bo Pang, Lulu Zhang, Bin Li, et al.
Physiology & Behavior (2023) Vol. 263, pp. 114134-114134
Closed Access | Times Cited: 12
Improving insulin resistance by sulforaphane via activating the Bacteroides and Lactobacillus SCFAs–GPR–GLP1 signal axis
Si-Cong Tian, Yiting Lei, Fangling Zhao, et al.
Food & Function (2024) Vol. 15, Iss. 17, pp. 8644-8660
Closed Access | Times Cited: 4
Integrative Study of Plantago lanceolata L.: Phytochemical Properties and Therapeutic Effects on Cancer, Diabetes, and Alzheimer’s Disease
Abdurrahim Kadı, Sena Öner, Hafize Yuca, et al.
Natural Product Research (2025), pp. 1-11
Closed Access
Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer’s disease in type 2 diabetes
Prakash Ramakrishan, Jayaraman Rajangam, Shaheedha Shabudeen Mahinoor, et al.
Metabolic Brain Disease (2025) Vol. 40, Iss. 3
Closed Access
Reducing Alzheimer’s Disease Risk with SGLT2 Inhibitors: From Glycemic Control to Neuroprotection
Mehdi Alami, Mojgan Morvaridzadeh, Abdellatif El Khayari, et al.
Ageing Research Reviews (2025), pp. 102751-102751
Closed Access
Sodium‐glucose cotransporter‐2 inhibitors and subtype‐specific dementia risk: A multinational and multiethnic cohort study
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure
Matteo Armillotta, Francesco Angeli, Pasquale Paolisso, et al.
Pharmacology & Therapeutics (2025) Vol. 270, pp. 108861-108861
Open Access
Comparative study of SGLT2 inhibitors and metformin: evaluating first-line therapies for dementia prevention in type 2 diabetes
Mingyang Sun, Xiaoling Wang, Zhongyuan Lu, et al.
Diabetes & Metabolism (2025), pp. 101655-101655
Closed Access
Risks and Benefits of SGLT-2 Inhibitors for Type 1 Diabetes Patients Using Automated Insulin Delivery Systems—A Literature Review
Viviana Elian, Violeta Popovici, Oana Karampelas, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 4, pp. 1972-1972
Open Access | Times Cited: 3
Insights from insulin resistance pathways: Therapeutic approaches against Alzheimer associated diabetes mellitus
Ayesha Fauzi, Ewen Se Thoe, Yin-Quan Tang, et al.
Journal of Diabetes and its Complications (2023) Vol. 37, Iss. 11, pp. 108629-108629
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top